[{"id":"4cfc19cf-1a63-442c-b2f4-a73392edd470","acronym":"","url":"https://clinicaltrials.gov/study/NCT04939701","created_at":"2021-06-25T22:54:10.185Z","updated_at":"2024-07-02T16:35:29.993Z","phase":"Phase 1/2","brief_title":"Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants","source_id_and_acronym":"NCT04939701","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" PD-L1 • CTAG1B • SSX1","pipe":" | ","alterations":" CTAG1B expression","tags":["PD-L1 • CTAG1B • SSX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ASP0739"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 01/11/2022","start_date":" 01/11/2022","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2023-11-08"}]